Understanding the process of fibrosis in duchenne muscular dystrophy

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Kharraz, Yacine ^a   Guerra, Joana ^a   Pessina, Patrizia ^a   Serrano, Antonio L ^a   Muñoz Cánoves, Pura ^a  

^a INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ALPHA 2 ANTIPLASMIN; ANGIOTENSIN II; ANGIOTENSIN[1-7]; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE; FOCAL ADHESION KINASE 1; GELATINASE; GELATINASE B; IMATINIB; INTERSTITIAL COLLAGENASE; LISINOPRIL; LOSARTAN; MATRILYSIN; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MYOGENIN; NEUTROPHIL COLLAGENASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; STROMELYSIN; STROMELYSIN 2; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; DYSTROPHIN;

DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; EXTRACELLULAR MATRIX; HUMAN; MESENCHYMAL STEM CELL; MUSCLE ATROPHY; MUSCLE NECROSIS; MYOFIBROSIS; NONHUMAN; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; STEM CELL; ANIMAL; FIBROSIS; GENETICS; METABOLISM; PATHOLOGY; SKELETAL MUSCLE SATELLITE CELL;

ANIMALS; DYSTROPHIN; FIBROSIS; HUMANS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; SATELLITE CELLS, SKELETAL MUSCLE;

EID: 84901788589     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/965631     Document Type: Review

References (101)

1. Emery A. E. H., The muscular dystrophies. The Lancet 2002 359 9307 687 695 2-s2.0-0037160782 10.1016/S0140-6736(02)07815-7 (Pubitemid 34203773)
2. Leung D. G., Wagner K. R., Therapeutic advances in muscular dystrophy. Annals of Neurology 2013 74 404 411
3. Ruegg U. T., Pharmacological prospects in the treatment of Duchenne muscular dystrophy. Current Opinion in Neurology 2013 26 577 584
4. Meregalli M., Farini A., Belicchi M., Parolini D., Cassinelli L., Razini P., Sitzia C., Torrente Y., Perspectives of stem cell therapy in Duchenne muscular dystrophy. FEBS Journal 2013 280 4251 4262
5. Benedetti S., Hoshiya H., Tedesco F. S., Repair or replace? Exploiting novel gene and cell therapy strategies for muscular dystrophies. FEBS Journal 2013 280 4263 4280
6. Briggs D., Morgan J. E., Recent progress in satellite cell/myoblast engraftment-relevance for therapy. FEBS Journal 2013 280 4281 4293
7. Konieczny P., Swiderski K., Chamberlain J. S., Gene and cell-mediated therapies for muscular dystrophy. Muscle & Nerve 2013 47 649 663
8. Mann C. J., Perdiguero E., Kharraz Y., Aguilar S., Pessina P., Serrano A. L., Munoz-Canoves P., Aberrant repair and fibrosis development in skeletal muscle. Skeletal Muscle 2011 1, article 21
9. Schessl J., Zou Y., Bönnemann C. G., Congenital muscular dystrophies and the extracellular matrix. Seminars in Pediatric Neurology 2006 13 2 80 89 2-s2.0-33749248495 10.1016/j.spen.2006.06.003 (Pubitemid 44486822)
10. MacDonald E. M., Cohn R. D., TGFbeta signaling: its role in fibrosis formation and myopathies. Current Opinion in Rheumatology 2012 24 628 634
11. Lieber R. L., Ward S. R., Cellular mechanisms of tissue fibrosis-4. Structural and functional consequences of skeletal muscle fibrosis. American Journal of Physiology. Cell Physiology 2013 305 C241 C252
12. Serrano A. L., Muñoz-Cánoves P., Regulation and dysregulation of fibrosis in skeletal muscle. Experimental Cell Research 2010 316 18 3050 3058 2-s2.0-77957669313 10.1016/j.yexcr.2010.05.035
13. Bowen T., Jenkins R. H., Fraser D. J., MicroRNAs, transforming growth factor beta-1, and tissue fibrosis. Journal of Pathology 2013 229 274 285
14. Zhou L., Porter J. D., Cheng G., Gong B., Hatala D. A., Merriam A. P., Zhou X., Rafael J. A., Kaminski H. J., Temporal and spatial mRNA expression patterns of TGF- β 1, 2, 3 and T β RI, II, III in skeletal muscles of mdx mice. Neuromuscular Disorders 2006 16 1 32 38 2-s2.0-30644470664 10.1016/j.nmd.2005.09.009 (Pubitemid 43089624)
15. Horiguchi M., Ota M., Rifkin D. B., Matrix control of transforming growth factor-beta function. Journal of Biochemistry 2013 152 321 329
16. Vidal B., Serrano A. L., Tjwa M., Suelves M., Ardite E., De Mori R., Baeza-Raja B., De Lagrán M. M., Lafuste P., Ruiz-Bonilla V., Jardí M., Gherardi R., Christov C., Dierssen M., Carmeliet P., Degen J. L., Dewerchin M., Muñoz-Cánoves P., Fibrinogen drives dystrophic muscle fibrosis via a TGF β /alternative macrophage activation pathway. Genes and Development 2008 22 13 1747 1752 2-s2.0-46249086678 10.1101/gad.465908 (Pubitemid 351915499)
17. Ardite E., Perdiguero E., Vidal B., Gutarra S., Serrano A. L., Muñoz-Cánoves P., PAI-1-regulated miR-21 defines a novel age-associated fibrogenic pathway in muscular dystrophy. Journal of Cell Biology 2012 196 1 163 175 2-s2.0-84856695092 10.1083/jcb.201105013
18. Wynn T. A., Cellular and molecular mechanisms of fibrosis. Journal of Pathology 2008 214 2 199 210 2-s2.0-38549159026 10.1002/path.2277 (Pubitemid 351160157)
19. Samarakoon R., Dobberfuhl A. D., Cooley C., Induction of renal fibrotic genes by TGF-beta1 requires EGFR activation, p53 and reactive oxygen species. Cellular Signalling 2013 25 2198 2209
20. Wynn T. A., Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. Journal of Clinical Investigation 2007 117 3 524 529 2-s2.0-33847350691 10.1172/JCI31487 (Pubitemid 46348506)
21. Shi Y., Massagué J., Mechanisms of TGF- β signaling from cell membrane to the nucleus. Cell 2003 113 6 685 700 2-s2.0-0038682002 10.1016/S0092-8674(03)00432-X (Pubitemid 36724933)
22. Shi-Wen X., Parapuram S. K., Pala D., Chen Y., Carter D. E., Eastwood M., Denton C. P., Abraham D. J., Leask A., Requirement of transforming growth factor β -activated kinase 1 for transforming growth factor β -induced α -smooth muscle actin expression and extracellular matrix contraction in fibroblasts. Arthritis and Rheumatism 2009 60 1 234 241 2-s2.0-58249109358 10.1002/art.24223
23. Dong Y., Lakhia R., Thomas S. S., Wang X. H., Silva K. A., Zhang L., Interactions between p-Akt and Smad3 in injured muscles initiate myogenesis or fibrogenesis. American Journal of Physiology. Endocrinology and Metabolism 2013 305 E367 E375
24. Brandan E., Cabello-Verrugio C., Vial C., Novel regulatory mechanisms for the proteoglycans decorin and biglycan during muscle formation and muscular dystrophy. Matrix Biology 2008 27 8 700 708 2-s2.0-56949083199 10.1016/j.matbio.2008.07.004
25. Li Y., Foster W., Deasy B. M., Chan Y., Prisk V., Tang Y., Cummins J., Huard J., Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. American Journal of Pathology 2004 164 3 1007 1019 2-s2.0-1242293760 (Pubitemid 38235482)
26. Li Y., Li J., Zhu J., Sun B., Branca M., Tang Y., Foster W., Xiao X., Huard J., Decorin gene transfer promotes muscle cell differentiation and muscle regeneration. Molecular Therapy 2007 15 9 1616 1622 2-s2.0-34548072165 10.1038/sj.mt.6300250 (Pubitemid 47289004)
27. Narola J., Pandey S. N., Glick A., Chen Y. W., Conditional expression of TGF-beta1 in skeletal muscles causes endomysial fibrosis and myofibers atrophy. PLoS ONE 2013 8 e79356
28. Heydemann A., Ceco E., Lim J. E., Hadhazy M., Ryder P., Moran J. L., Beier D. R., Palmer A. A., McNally E. M., Latent TGF- β -binding protein 4 modifies muscular dystrophy in mice. Journal of Clinical Investigation 2009 119 12 3703 3712 2-s2.0-72849135317 10.1172/JCI39845
29. Sun G., Haginoya K., Wu Y., Chiba Y., Nakanishi T., Onuma A., Sato Y., Takigawa M., Iinuma K., Tsuchiya S., Connective tissue growth factor is overexpressed in muscles of human muscular dystrophy. Journal of the Neurological Sciences 2008 267 1-2 48 56 2-s2.0-39049164607 10.1016/j.jns.2007. 09.043 (Pubitemid 351248904)
30. Morales M. G., Gutierrez J., Cabello-Verrugio C., Cabrera D., Lipson K. E., Goldschmeding R., Brandan E., Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy. Human Molecular Genetics 2013 22 4938 4951
31. Frazier K., Williams S., Kothapalli D., Klapper H., Grotendorst G. R., Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. Journal of Investigative Dermatology 1996 107 3 404 411 2-s2.0-0029816069 (Pubitemid 26284351)
32. Morales M. G., Cabello-Verrugio C., Santander C., Cabrera D., Goldschmeding R., Brandan E., CTGF/CCN-2 over-expression can directly induce features of skeletal muscle dystrophy. Journal of Pathology 2011 225 4 490 501 2-s2.0-81355149683 10.1002/path.2952
33. Vial C., Gutiérrez J., Santander C., Cabrera D., Brandan E., Decorin interacts with connective tissue growth factor (CTGF)/CCN2 by LRR12 inhibiting its biological activity. Journal of Biological Chemistry 2011 286 27 24242 24252 2-s2.0-79959865250 10.1074/jbc.M110.189365
34. Vial C., Zúñiga L. M., Cabello-Verrugio C., Cañón P., Fadic R., Brandan E., Skeletal muscle cells express the profibrotic cytokine connective tissue growth factor (CTGF/CCN2), which induces their dedifferentiation. Journal of Cellular Physiology 2008 215 2 410 421 2-s2.0-40949152810 10.1002/jcp.21324 (Pubitemid 351468953)
35. Morales M. G., Cabrera D., Cespedes C., Vio C. P., Vazquez Y., Brandan E., Cabello-Verrugio C., Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2). Cell and Tissue Research 2013 353 173 187
36. Vío C. P., Jeanneret V. A., Local induction of angiotensin-converting enzyme in the kidney as a mechanism of progressive renal diseases. Kidney International 2003 64 86 S57 S63 2-s2.0-17944389392 (Pubitemid 37159629)
37. Sun G., Haginoya K., Dai H., Chiba Y., Uematsu M., Hino-Fukuyo N., Onuma A., Iinuma K., Tsuchiya S., Intramuscular renin-angiotensin system is activated in human muscular dystrophy. Journal of the Neurological Sciences 2009 280 1-2 40 48 2-s2.0-63349085819 10.1016/j.jns.2009.01.020
38. Cabello-Verrugio C., Acuña M. J., Morales M. G., Becerra A., Simon F., Brandan E., Fibrotic response induced by angiotensin-II requires NAD(P)H oxidase-induced reactive oxygen species (ROS) in skeletal muscle cells. Biochemical and Biophysical Research Communications 2011 410 3 665 670 2-s2.0-79960062769 10.1016/j.bbrc.2011.06.051
39. Painemal P., Acuna M. J., Riquelme C., Brandan E., Cabello-Verrugio C., Transforming growth factor type beta 1 increases the expression of angiotensin II receptor type 2 by a SMAD- and p38 MAPK-dependent mechanism in skeletal muscle. Biofactors 2013 39 467 475
40. Acuna M. J., Pessina P., Olguin H., Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-beta signalling. Human Molecular Genetics 2014 23 1237 1249
41. Chen X., Li Y., Role of matrix metalloproteinases in skeletal muscle: migration, differentiation, regeneration and fibrosis. Cell Adhesion & Migration 2009 3 4 337 341 2-s2.0-77649197352
42. Nagamine Y., Medcalf R. L., Muñoz-Cánoves P., Transcriptional and posttranscriptional regulation of the plasminogen activator system. Thrombosis and Haemostasis 2005 93 4 661 675 2-s2.0-16844362873 10.1160/TH04-12-0814 (Pubitemid 40485401)
43. Suelves M., Vidal B., Ruiz V., Baeza-Raja B., Diaz-Ramos A., Cuartas I., Lluis F., Parra M., Jardi M., Lopez-Alemany R., Serrano A. L., Munoz-Canoves P., The plasminogen activation system in skeletal muscle regeneration: antagonistic roles of Urokinase-type Plasminogen Activator (UPA) and its inhibitor (PAI-1). Frontiers in Bioscience 2005 10 3 2978 2985 2-s2.0-21344452350 (Pubitemid 40910536)
44. Ohtake Y., Tojo H., Seiki M., Multifunctional roles of MT1-MMP in myofiber formation and morphostatic maintenance of skeletal muscle. Journal of Cell Science 2006 119 18 3822 3832 2-s2.0-33750325693 10.1242/jcs.03158 (Pubitemid 44614434)
45. Visse R., Nagase H., Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circulation Research 2003 92 8 827 839 2-s2.0-0037693895 10.1161/01.RES.0000070112.80711.3D (Pubitemid 36542523)
46. Suelves M., Vidal B., Serrano A. L., Tjwa M., Roma J., López-Alemany R., Luttun A., De Lagrán M. M., Díaz M. À., Jardí M., Roig M., Dierssen M., Dewerchin M., Carmeliet P., Muñoz-Cánoves P., uPA deficiency exacerbates muscular dystrophy in MDX mice. Journal of Cell Biology 2007 178 6 1039 1051 2-s2.0-34548829943 10.1083/jcb.200705127 (Pubitemid 47443325)
47. Zanotti S., Negri T., Cappelletti C., Bernasconi P., Canioni E., Di Blasi C., Pegoraro E., Angelini C., Ciscato P., Prelle A., Mantegazza R., Morandi L., Mora M., Decorin and biglycan expression is differentially altered in several muscular dystrophies. Brain 2005 128 11 2546 2555 2-s2.0-27644532724 10.1093/brain/awh635 (Pubitemid 41552940)
48. Arnold L., Henry A., Poron F., Baba-Amer Y., Van Rooijen N., Plonquet A., Gherardi R. K., Chazaud B., Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. Journal of Experimental Medicine 2007 204 5 1057 1069 2-s2.0-34248997759 10.1084/jem.20070075 (Pubitemid 46798150)
49. Kharraz Y., Guerra J., Mann C. J., Serrano A. L., Munoz-Canoves P., Macrophage plasticity and the role of inflammation in skeletal muscle repair. Mediators of Inflammation 2013 2013 9 10.1155/2013/491497 491497
50. Wehling M., Spencer M. J., Tidball J. G., A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. Journal of Cell Biology 2001 155 1 123 131 2-s2.0-0035494438 10.1083/jcb.200105110 (Pubitemid 34286213)
51. Gordon S., Alternative activation of macrophages. Nature Reviews Immunology 2003 3 1 23 35 2-s2.0-0037265240 10.1038/nri978 (Pubitemid 37328697)
52. Wynn T. A., Fibrotic disease and the TH1/TH2 paradigm. Nature Reviews Immunology 2004 4 8 583 594 2-s2.0-3543107212
53. Desguerre I., Christov C., Mayer M., Zeller R., Becane H.-M., Bastuji-Garin S., Leturcq F., Chiron C., Chelly J., Gherardi R. K., Clinical heterogeneity of Duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up. PLoS ONE 2009 4 2 2-s2.0-61449094869 10.1371/journal.pone.0004347 e4347
54. Villalta S. A., Nguyen H. X., Deng B., Gotoh T., Tidbal J. G., Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Human Molecular Genetics 2009 18 3 482 496 2-s2.0-58749098598 10.1093/hmg/ddn376
55. Wehling-Henricks M., Jordan M. C., Gotoh T., Grody W. W., Roos K. P., Tidball J. G., Arginine metabolism by macrophages promotes cardiac and muscle fibrosis in mdx muscular dystrophy. PloS ONE 2010 5 5 e10763 2-s2.0-77956283573 10.1371/journal.pone.0010763
56. Ryu J. K., Davalos D., Akassoglou K., Fibrinogen signal transduction in the nervous system. Journal of Thrombosis and Haemostasis 2009 7 1 151 154 2-s2.0-67849121525 10.1111/j.1538-7836.2009.03438.x
57. Vidal B., Ardite E., Suelves M., Ruiz-Bonilla V., Janué A., Flick M. J., Degen J. L., Serrano A. L., Muñoz-Cánoves P., Amelioration of Duchenne muscular dystrophy in mdx mice by elimination of matrix-associated fibrin-driven inflammation coupled to the α m β 2 leukocyte integrin receptor. Human Molecular Genetics 2012 21 9 1989 2004 2-s2.0-84859308196 10.1093/hmg/dds012
58. Farini A., Meregalli M., Belicchi M., Battistelli M., Parolini D., D'Antona G., Gavina M., Ottoboni L., Constantin G., Bottinelli R., Torrente Y., T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse. Journal of Pathology 2007 213 2 229 238 2-s2.0-35349000178 10.1002/path.2213 (Pubitemid 47612245)
59. Morrison J., Lu Q. L., Pastoret C., Partridge T., Bou-Gharios G., T-cell-dependent fibrosis in the mdx dystrophic mouse. Laboratory Investigation 2000 80 6 881 891 2-s2.0-0033918282 (Pubitemid 30421805)
60. Spencer M. J., Montecino-Rodriguez E., Dorshkind K., Tidball J. G., Helper (CD4+) and cytotoxic (CD8+) T cells promote the pathology of dystrophin-deficient muscle. Clinical Immunology 2001 98 2 235 243 2-s2.0-0035122405 10.1006/clim.2000.4966 (Pubitemid 32150612)
61. Vetrone S. A., Montecino-Rodriguez E., Kudryashova E., Kramerova I., Hoffman E. P., Liu S. D., Miceli M. C., Spencer M. J., Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF- β Journal of Clinical Investigation 2009 119 6 1583 1594 2-s2.0-67651005390 10.1172/JCI37662
62. Pagel C. N., Wasgewatte Wijesinghe D. K., Taghavi Esfandouni N., Mackie E. J., Osteopontin, inflammation and myogenesis: influencing regeneration, fibrosis and size of skeletal muscle. Journal of Cell Communication and Signaling 2013
63. Barron L., Wynn T. A., Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. American Journal of Physiology. Gastrointestinal and Liver Physiology 2011 300 5 G723 G728 2-s2.0-79955565441 10.1152/ajpgi.00414.2010
64. Lo Re S., Lison D., Huaux F., CD4+ T lymphocytes in lung fibrosis: diverse subsets, diverse functions. Journal of Leukocyte Biology 2013 93 499 510
65. Joe A. W. B., Yi L., Natarajan A., Le Grand F., So L., Wang J., Rudnicki M. A., Rossi F. M. V., Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nature Cell Biology 2010 12 2 153 163 2-s2.0-75949096894 10.1038/ncb2015
66. Uezumi A., Fukada S.-I., Yamamoto N., Takeda S., Tsuchida K., Mesenchymal progenitors distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle. Nature Cell Biology 2010 12 2 143 152 2-s2.0-75949130333 10.1038/ncb2014
67. Murphy M. M., Lawson J. A., Mathew S. J., Hutcheson D. A., Kardon G., Satellite cells, connective tissue fibroblasts and their interactions are crucial for muscle regeneration. Development 2011 138 17 3625 3637 2-s2.0-80051542088 10.1242/dev.064162
68. Mathew S. J., Hansen J. M., Merrell A. J., Murphy M. M., Lawson J. A., Hutcheson D. A., Hansen M. S., Angus-Hill M., Kardon G., Connective tissue fibroblasts and Tcf4 regulate myogenesis. Development 2011 138 2 371 384 2-s2.0-78751475042 10.1242/dev.057463
69. Judson R. N., Zhang R. H., Rossi F. M., Tissue-resident mesenchymal stem/progenitor cells in skeletal muscle: collaborators or saboteurs? FEBS Journal 2013 280 4100 4108
70. Uezumi A., Ito T., Morikawa D., Shimizu N., Yoneda T., Segawa M., Yamaguchi M., Ogawa R., Matev M. M., Miyagoe-Suzuki Y., Takeda S., Tsujikawa K., Tsuchida K., Yamamoto H., Fukada S.-I., Fibrosis and adipogenesis originate from a common mesenchymal progenitor in skeletal muscle. Journal of Cell Science 2011 124 21 3654 3664 2-s2.0-81355149472 10.1242/jcs.086629
71. Dulauroy S., di Carlo S. E., Langa F., Eberl G., Peduto L., Lineage tracing and genetic ablation of ADAM12(+) perivascular cells identify a major source of profibrotic cells during acute tissue injury. Nature Medicine 2012 18 1262 1270
72. Jørgensen L. H., Jensen C. H., Wewer U. M., Schrøder H. D., Transgenic overexpression of ADAM12 suppresses muscle regeneration and aggravates dystrophy in aged mdx mice. American Journal of Pathology 2007 171 5 1599 1607 2-s2.0-36348958434 10.2353/ajpath.2007.070435 (Pubitemid 350158320)
73. LeBleu V. S., Taduri G., O'Connell J., Origin and function of myofibroblasts in kidney fibrosis. Nature Medicine 2013 19 1047 1053
74. Wu S. M., Chien K. R., Mummery C., Origins and fates of cardiovascular progenitor cells. Cell 2008 132 4 537 543 2-s2.0-39149126371 10.1016/j.cell.2008.02.002 (Pubitemid 351253695)
75. Brack A. S., Conboy M. J., Roy S., Lee M., Kuo C. J., Keller C., Rando T. A., Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science 2007 317 5839 807 810 2-s2.0-34547924424 10.1126/science.1144090 (Pubitemid 47257918)
76. Zordan P., Rigamonti E., Freudenberg K., Macrophages commit postnatal endothelium-derived progenitors to angiogenesis and restrict endothelial to mesenchymal transition during muscle regeneration. Cell Death & Disease 2014 5 e1031
77. Carnwath J. W., Shotton D. M., Muscular dystrophy in the mdx mouse: histopathology of the soleus and extensor digitorum longus muscles. Journal of the Neurological Sciences 1987 80 1 39 54 2-s2.0-0023244894 (Pubitemid 17094623)
78. Banks G. B., Chamberlain J. S., The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies. Current Topics in Developmental Biology 2008 84 431 453 2-s2.0-58749101371 10.1016/S0070-2153(08)00609-1
79. Zhou L., Rafael-Fortney J. A., Huang P., Zhao X. S., Cheng G., Zhou X., Kaminski H. J., Liu L., Ransohoff R. M., Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice. Journal of the Neurological Sciences 2008 264 1-2 106 111 2-s2.0-36549027365 10.1016/j.jns.2007.08.029 (Pubitemid 350186318)
80. Sacco A., Mourkioti F., Tran R., Choi J., Llewellyn M., Kraft P., Shkreli M., Delp S., Pomerantz J. H., Artandi S. E., Blau H. M., Short telomeres and stem cell exhaustion model duchenne muscular dystrophy in mdx/mTR mice. Cell 2010 143 7 1059 1071 2-s2.0-78650432352 10.1016/j.cell.2010.11.039
81. Mourkioti F., Kustan J., Kraft P., Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy. Nature Cell Biology 2013 15 895 904
82. Chandrasekharan K., Yoon J. H., Xu Y., DeVries S., Camboni M., Janssen P. M. L., Varki A., Martin P. T., A human-specific deletion in mouse Cmah increases disease severity in the mdx model of duchenne muscular dystrophy. Science Translational Medicine 2010 2 42 2-s2.0-77955634766 10.1126/ scitranslmed.3000692 42ra54
83. Martin P. T., Camboni M., Xu R., N-Glycolylneuraminic acid deficiency worsens cardiac and skeletal muscle pathophysiology in alpha-sarcoglycan- deficient mice. Glycobiology 2013 23 833 843
84. Fukada S.-I., Morikawa D., Yamamoto Y., Yoshida T., Sumie N., Yamaguchi M., Ito T., Miyagoe-Suzuki Y., Takeda S., Tsujikawa K., Yamamoto H., Genetic background affects properties of satellite cells and mdx phenotypes. American Journal of Pathology 2010 176 5 2414 2424 2-s2.0-77952066105 10.2353/ajpath.2010.090887
85. Desguerre I., Arnold L., Vignaud A., A new model of experimental fibrosis in hindlimb skeletal muscle of adult mdx mouse mimicking muscular dystrophy. Muscle Nerve 2012 45 803 814
86. de Luca A., Pierno S., Liantonio A., Cetrone M., Camerino C., Fraysse B., Mirabella M., Servidei S., Rüegg U. T., Conte Camerino D., Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. Journal of Pharmacology and Experimental Therapeutics 2003 304 1 453 463 2-s2.0-0037215644 10.1124/jpet.102.041343 (Pubitemid 36008959)
87. Menetrey J., Kasemkijwattana C., Fu F. H., Moreland M. S., Huard J., Suturing versus immobilization of a muscle laceration. A morphological and functional study in a mouse model. American Journal of Sports Medicine 1999 27 2 222 229 2-s2.0-0032987965 (Pubitemid 29138545)
88. Carlson B. M., Billington L., Faulkner J., Studies on the regenerative recovery of long-term denervated muscle in rats. Restorative Neurology and Neuroscience 1996 10 2 77 84 2-s2.0-0029739030 (Pubitemid 26329429)
89. Abdel-Hamid H., Clemens P. R., Pharmacological therapies for muscular dystrophies. Current Opinion in Neurology 2012 25 604 608
90. Elbaz M., Yanay N., Aga-Mizrachi S., Brunschwig Z., Kassis I., Ettinger K., Barak V., Nevo Y., Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy2J/dy2J mouse. Annals of Neurology 2012 71 5 699 708 2-s2.0-84860186068 10.1002/ana.22694
91. Burks T. N., Andres-Mateos E., Marx R., Mejias R., Van Erp C., Simmers J. L., Walston J. D., Ward C. W., Cohn R. D., Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Science Translational Medicine 2011 3 82 2-s2.0-79955882466 10.1126/scitranslmed.3002227 82ra37
92. Park J. K., Ki M. R., Lee E. M., Losartan improves adipose tissue-derived stem cell niche by inhibiting transforming growth factor-beta and fibrosis in skeletal muscle injury. Cell Transplantation 2012 21 2407 2424
93. Bish L. T., Yarchoan M., Sleeper M. M., Gazzara J. A., Morine K. J., Acosta P., Barton E. R., Sweeney H. L., Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice. PLoS ONE 2011 6 6 2-s2.0-79959442500 10.1371/journal.pone.0020856 e20856
94. Rafael-Fortney J. A., Chimanji N. S., Schill K. E., Martin C. D., Murray J. D., Ganguly R., Stangland J. E., Tran T., Xu Y., Canan B. D., Mays T. A., Delfín D. A., Janssen P. M. L., Raman S. V., Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in duchenne muscular dystrophy mice. Circulation 2011 124 5 582 588 2-s2.0-80051552743 10.1161/CIRCULATIONAHA.111.031716
95. Allen H. D., Flanigan K. M., Thrush P. T., A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy. PLoS Currents 2013
96. Andreetta F., Bernasconi P., Baggi F., Ferro P., Oliva L., Arnoldi E., Cornelio F., Mantegazza R., Confalonieri P., Immunomodulation of TGF-beta1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy. Journal of Neuroimmunology 2006 175 1-2 77 86 2-s2.0-33746318677 10.1016/j.jneuroim.2006. 03.005
97. Bizario J. C. D. S., Cerri D. G., Rodrigues L. C., Oliveira G. L. V., Nomizo A., de Araujo D. D., Fukuhara P. S., Ribeiro J. C., de Castro F. A., Costa M. C. R., Imatinib mesylate ameliorates the dystrophic phenotype in exercised mdx mice. Journal of Neuroimmunology 2009 212 1-2 93 101 2-s2.0-67649871093 10.1016/j.jneuroim.2009.05.006
98. Ito T., Ogawa R., Uezumi A., Imatinib attenuates severe mouse dystrophy and inhibits proliferation and fibrosis-marker expression in muscle mesenchymal progenitors. Neuromuscular Disorders 2013 23 349 356
99. Pines M., Halevy O., Halofuginone and muscular dystrophy. Histology and Histopathology 2011 26 1 135 146 2-s2.0-78651258934
100. Huebner K. D., Jassal D. S., Halevy O., Pines M., Anderson J. E., Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone. American Journal of Physiology. Heart and Circulatory Physiology 2008 294 4 H1550 H1561 2-s2.0-41749095368 10.1152/ajpheart.01253.2007 (Pubitemid 351490584)
101. Sundrud M. S., Koralov S. B., Feuerer M., Calado D. P., Kozhaya A. E., Rhule-Smith A., Lefebvre R. E., Unutmaz D., Mazitschek R., Waldner H., Whitman M., Keller T., Rao A., Halofuginone inhibits th17 cell differentiation by activating the amino acid starvation response. Science 2009 324 5932 1334 1338 2-s2.0-66749107425 10.1126/science.1172638